• 1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

Recent Advances in the Study of 3-Pyridinecarboxylic acid, 5-bromo-4-ethyl- (CAS: 2167106-90-1) and Its Applications in Chemical Biology and Medicine

3-Pyridinecarboxylic acid, 5-bromo-4-ethyl- (CAS: 2167106-90-1) is a brominated pyridine derivative that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by its unique structural features, has been investigated for its role as a building block in the synthesis of novel bioactive molecules and its interactions with biological targets. Recent studies have explored its utility in drug discovery, particularly in the development of enzyme inhibitors and receptor modulators.

One of the key areas of research involving 3-Pyridinecarboxylic acid, 5-bromo-4-ethyl- is its use as a precursor in the synthesis of heterocyclic compounds with potential therapeutic effects. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit promising activity against certain kinase enzymes, which are often implicated in cancer and inflammatory diseases. The study highlighted the compound's ability to form stable interactions with the ATP-binding sites of these enzymes, suggesting its potential as a scaffold for kinase inhibitor development.

In addition to its role in kinase inhibition, recent research has also explored the compound's applications in antimicrobial drug development. A 2022 paper in Bioorganic & Medicinal Chemistry Letters reported that 3-Pyridinecarboxylic acid, 5-bromo-4-ethyl- derivatives displayed moderate to strong activity against a range of bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The study attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, making it a candidate for further optimization in antibiotic design.

Another significant development is the use of 3-Pyridinecarboxylic acid, 5-bromo-4-ethyl- in the design of fluorescent probes for biological imaging. A 2023 study in Chemical Communications detailed the synthesis of a novel probe based on this compound, which exhibited high selectivity for certain metal ions in cellular environments. This application underscores the compound's versatility beyond traditional drug discovery, extending its utility to diagnostic and imaging technologies.

Despite these promising findings, challenges remain in the optimization of 3-Pyridinecarboxylic acid, 5-bromo-4-ethyl- derivatives for clinical use. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed through further structural modifications and in vivo studies. However, the compound's unique chemical properties and demonstrated biological activities position it as a valuable tool in the ongoing quest for new therapeutic agents and biochemical tools.

In conclusion, recent research on 3-Pyridinecarboxylic acid, 5-bromo-4-ethyl- (CAS: 2167106-90-1) highlights its multifaceted potential in chemical biology and medicine. From kinase inhibition to antimicrobial activity and imaging applications, this compound continues to inspire innovative approaches in drug discovery and biomedical research. Future studies will likely focus on refining its derivatives to overcome current limitations and unlock its full therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)